glp-1 receptor agonists alternatives to ozempic Type 2 diabetes: New pill now available in the U.S Ozempic, GLP-1 Drugs & the

In a new study published yesterday in JAMA Ophthalmology , researchers looked at retrospective electronic health record network data comprising patients with and without diabetes who received prescriptions for GLP-1 drugs, metformin, insulin or sodium-glucose cotransporter 2 inhibitors (SGLT2i)

Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study

Although the existing evidence in HFpEF is compelling, further trials seem warranted, particularly with respect to the effects of GLP-1 RAs on clinical outcomes and, possibly, in broader patient populations, such as patients with HFrEF or those without obesity.

Additionally, a potential synergistic mechanism may exist between SGLT2 inhibitors and GLP-1RAs in the management of NASH [42]

pH stability and activity curves of pepsin with special reference to their clinical importance

However, as this analysis was conducted post hoc, the findings should be interpreted with caution and considered hypothesis-generating rather than evidence of superiority between agents